Cargando…

IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide

Prior studies implicate type 1 IGF receptor (IGF-1R) in mediating chemo-resistance. Here, we investigated whether IGF-1R influences response to temozolomide (TMZ), which generates DNA adducts that are removed by O(6)-methylguanine-DNA methyltransferase (MGMT), or persist causing replication-associat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramcharan, Roger, Aleksic, Tamara, Kamdoum, Wilfride Petnga, Gao, Shan, Pfister, Sophia X., Tanner, Jordan, Bridges, Esther, Asher, Ruth, Watson, Amanda J., Margison, Geoffrey P., Woodcock, Mick, Repapi, Emmanouela, Li, Ji-Liang, Middleton, Mark R., Macaulay, Valentine M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741867/ https://www.ncbi.nlm.nih.gov/pubmed/26497996

Ejemplares similares

Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
por: Simpson, Aaron, et al.
Publicado: (2017)

Growth Kinetics of Bacterial Pili from Pairwise Pilin Association Rates
por: Monteiro, Diana C. F., et al.
Publicado: (2013)

IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination
por: Chitnis, Meenali M., et al.
Publicado: (2013)

Type 1 IGF receptor associates with adverse outcome and cellular radioresistance in paediatric high-grade glioma
por: Simpson, Aaron D., et al.
Publicado: (2019)

Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR
por: Aleksic, Tamara, et al.
Publicado: (2016)

Therapeutic Targeting of the IGF Axis
por: Osher, Eliot, et al.
Publicado: (2019)

On optimal temozolomide scheduling for slowly growing glioblastomas
por: Segura-Collar, Berta, et al.
Publicado: (2022)

Extended-schedule dose-dense temozolomide in refractory gliomas
por: Berrocal, A., et al.
Publicado: (2009)

IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer
por: Aleksic, Tamara, et al.
Publicado: (2017)

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer
por: Khan, O A, et al.
Publicado: (2008)

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer
por: Khan, O A, et al.
Publicado: (2009)

A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
por: Lee, S. M., et al.
Publicado: (1994)

Erratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma
por: Kefford, R F, et al.
Publicado: (2009)

Marked inactivation of O(6)-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
por: Tolcher, A W, et al.
Publicado: (2003)

IGF-1R nuclear import and recruitment to chromatin involves both alpha and beta subunits
por: Mills, Jack V., et al.
Publicado: (2021)

Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival
por: Robinson, C G, et al.
Publicado: (2010)

Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
por: Thomas, Katharine, et al.
Publicado: (2020)

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
por: Middleton, M. R., et al.
Publicado: (1998)

Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.
por: Baer, J. C., et al.
Publicado: (1993)

O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib
por: Watson, A J, et al.
Publicado: (2009)

O(6)-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts
por: Clemons, M, et al.
Publicado: (2005)

Barriers to and Facilitators of Automated Patient Self-scheduling for Health Care Organizations: Scoping Review
por: Woodcock, Elizabeth W
Publicado: (2022)

CHK1 inhibition exacerbates replication stress induced by IGF blockade
por: Wu, Xiaoning, et al.
Publicado: (2021)

Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
por: Lee, S. M., et al.
Publicado: (1993)

The Influence of the Scheduling Horizon on New Patient Arrivals
por: Woodcock, Elizabeth, et al.
Publicado: (2020)

Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status
por: Wu, Qiong, et al.
Publicado: (2023)

No evidence for age-related differences in mitochondrial RNA quality in the female germline
por: Hartley, Fiona, et al.
Publicado: (2022)

Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
por: Pfister, Sophia X., et al.
Publicado: (2015)

Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma Cells
por: Beltzig, Lea, et al.
Publicado: (2021)

Transforming Growth Factor β Drives Hemogenic Endothelium Programming and the Transition to Hematopoietic Stem Cells
por: Monteiro, Rui, et al.
Publicado: (2016)

The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death
por: Chen, Peng-Hsu, et al.
Publicado: (2016)

Does osteogenic potential of clonal human bone marrow mesenchymal stem/stromal cells correlate with their vascular supportive ability?
por: Merryweather-Clarke, Alison T., et al.
Publicado: (2018)

Chemotherapy of Capecitabine plus Temozolomide for Refractory Pituitary Adenoma after Tumor Resection and Its Impact on Serum Prolactin, IGF-1, and Growth Hormone
por: Wang, Xirui, et al.
Publicado: (2022)

LncRNA HOXA-AS2 Promotes Temozolomide Resistance in Glioblastoma by Regulated miR-302a-3p/IGF1 Axis
por: Lin, Ligang, et al.
Publicado: (2022)

Dose finding and O(6)-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies
por: Geoerger, B, et al.
Publicado: (2005)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

Temozolomide-Induced Myelodysplasia
por: Natelson, Ethan A., et al.
Publicado: (2010)

Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells
por: Ohba, Shigeo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dh46dvrmfbsd38qvr4u0qp11rf